ClinicalTrials.gg
CompletedNCT02392559HAUSER-RCTUpdated Nov 8, 2022Results posted

Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

A Phase 3 interventional study of Evolocumab and Placebo in Heterozygous Familial Hypercholesterolemia, sponsored by Amgen. Completed at 66 sites in 26 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.

Enrollment
25th of 36
158 · median 308
Started
2016
with 3 others
Phase 3
22 of 36
none open now
Registered
23rd of 36
by date
Lead sponsor
30 of 36
Amgen

Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 25th largest by enrollment, is one of 4 that started in 2016, is one of 22 in phase 3, and was the 23rd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing evolocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

A study to assess safety and efficacy of evolocumab (AMG-145) in paediatric subjects aged 10-17 years diagnosed with heterozygous familial hypercholesterolemia.

Read the detailed description

A study to evaluate the effect of 24 weeks of subcutaneous (SC) evolocumab compared with placebo, when added to standard of care, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in pediatric subjects 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH).

03

Conditions studied

  • Heterozygous Familial Hypercholesterolemia

Keywords

  • Hypercholesterolemia
  • Elevated Cholesterol
  • High Cholesterol
  • Heterozygous Familial Hypercholesterolemia
  • PCSK9 mutations
  • Paediatric
  • pediatric
  • Childhood Familial Hypercholesterolemia
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 10 to ≤ 17 years of age (before 18th birthday)
  • Diagnosis of heterozygous familial hypercholesterolemia
  • On an approved statin with stable optimized dose for ≥ 4 weeks
  • Other lipid-lowering therapy stable for ≥ 4 weeks (fibrates must be stable for ≥ 6 weeks)
  • Fasting LDL-C ≥ 130 mg/dL (3.4 mmol/L)
  • Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes, or type 2 diabetes that is or poorly controlled
  • Uncontrolled hyperthyroidism or hypothyroidism
  • Cholesterylester transfer protein (CETP) inhibitor in the last 12 months, or mipomersen or lomitapide in the last 5 months
  • Previously received evolocumab or any other therapy to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9).
  • Lipid apheresis within the last 12 weeks prior to screening.
  • Homozygous familial hypercholesterolemia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
158 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching subcutaneous injection every 4 weeks (QM)

    Drug: Placebo

  • Experimental
    EvoMab 420 mg QM

    Evolocumab subcutaneous injection QM

    Drug: Evolocumab

Interventions

  • Dose of subcutaneous evolocumab every 4 weeks

    Also known as: AMG 145; EvoMab

  • DrugPlacebo

    Dose of subcutaneous placebo treatment every 4 weeks

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 24 in LDL-C

    Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from interactive voice response system \[IVRS\]), scheduled visit and the interaction of treatment with scheduled visit as covariates. The model uses an unstructured covariance.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Mean Percent Change From Baseline to Mean of Weeks 22 and 24 in LDL-C

    Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Week 22, Week 24

  2. Change From Baseline to Week 24 in LDL-C

    Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Week 24

  3. Percent Change From Baseline to Week 24 in Non-HDL-C

    Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates

    Time frame: Baseline, Week 24

  4. Percent Change From Baseline to Week 24 in Apoliprotein-B (ApoB)

    Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Week 24

  5. Percent Change From Baseline to Week 24 in Total Cholesterol/HDL-C Ratio

    Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Week 24

  6. Percent Change From Baseline to Week 24 in ApoB:ApoA1 Ratio

    Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Week 24

  7. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation (DC), Fatal TEAEs, and Device-Related TEAEs

    An adverse event (AE) is defined as any untoward medical occurrence that does not necessarily have a causal relationship with study treatment. An SAE is defined as an adverse event that: is fatal; is a life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other medically important serious event. Events were graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grading scale (1=mild; 2=moderate; 3=severe; 4=life-threatening; 5=death). Events were defined as treatment emergent if they occurred after the first dose of study drug and up to and including 30 days after the last dose or the end of study date, whichever is earlier.

    Time frame: From first dose of study drug up to and including 30 days after the last dose or end of study date (Week 24), whichever was earlier. Mean (SD) duration on study was 5.664 (0.278) and 5.608 (0.137) months for Placebo and EvoMab arms, respectively.

  8. Number of Participants With Maximum Post-Baseline Laboratory Toxicities of Grade ≥ 3

    Laboratory toxicity grading was based on NCI CTCAE grading. Grade 3 indicates severe toxicity and Grade 4 indicates life-threatening toxicity. Values representing a worsening from baseline are shown.

    Time frame: Week 24

  9. Change From Baseline Over Time in Systolic Blood Pressure

    Time frame: Baseline, Week 4, Week 12, Week 20, Week 22, Week 24

  10. Change From Baseline Over Time in Diastolic Blood Pressure

    Time frame: Baseline, Week 4, Week 12, Week 20, Week 22, Week 24

  11. Change From Baseline Over Time in Heart Rate

    Time frame: Baseline, Week 4, Week 12, Week 20, Week 22, Week 24

  12. Number of Participants Testing Positive for Anti-Evolocumab Antibodies

    Time frame: up to Week 24

  13. Serum Evolocumab Concentrations Over Time

    Time frame: Week 12, Week 22, Week 24

07

Results

Posted Jul 15, 2020

Participant flow

Participants were enrolled from 24 March 2016 to 30 May 2019 at 8 research centers in North America, 30 research centers in Europe, 6 research centers in Latin America, and 3 research centers in Asia Pacific.

Participant flow — Overall Study
MilestonePlaceboEvoMab 420 mg QM
Started53105
Randomized and dosed53104
Completed53104
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryPercent Change From Baseline to Week 24 in LDL-C

Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from interactive voice response system \[IVRS\]), scheduled visit and the interaction of treatment with scheduled visit as covariates. The model uses an unstructured covariance.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 24 in LDL-C
percent changePlaceboEvoMab 420 mg QM
Percent Change From Baseline to Week 24 in LDL-C-6.23 ± 3.08-44.53 ± 2.17
Statistical analysis
  • Placebo vs EvoMab 420 mg QM · repeated measures model · p = < 0.0001 · Treatment difference: -38.30 · 95% CI -45.54 to -31.06Treatment difference uses placebo as the reference.
  • Placebo vs EvoMab 420 mg QM · sequential testing/Hochberg procedure · p = < 0.0001 (Adjusted p-value based on a combination of sequential testing and the Hochberg procedure to control the overall significance level for all primary and secondary endpoints.)Adjusted p-value is compared to 0.05 to determine statistical significance.
SecondaryMean Percent Change From Baseline to Mean of Weeks 22 and 24 in LDL-C

Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Week 22, Week 24
Reported as:
Least squares mean · percent change
Mean Percent Change From Baseline to Mean of Weeks 22 and 24 in LDL-C
percent changePlaceboEvoMab 420 mg QM
Mean Percent Change From Baseline to Mean of Weeks 22 and 24 in LDL-C-5.87 ± 2.66-47.95 ± 1.92
Statistical analysis
  • Placebo vs EvoMab 420 mg QM · repeated measures model · p = < 0.0001 · Treatment difference: -42.09 · 95% CI -48.34 to -35.83Treatment difference uses placebo as the reference.
  • Placebo vs EvoMab 420 mg QM · sequential testing/Hochberg procedure · p = < 0.0001 (Adjusted p-value based on a combination of sequential testing and the Hochberg procedure to control the overall significance level for all primary and secondary endpoints.)Adjusted p-value is compared to 0.05 to determine statistical significance.
SecondaryChange From Baseline to Week 24 in LDL-C

Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 24 in LDL-C
mg/dLPlaceboEvoMab 420 mg QM
Change From Baseline to Week 24 in LDL-C-9.0 ± 6.2-77.5 ± 4.4
Statistical analysis
  • Placebo vs EvoMab 420 mg QM · repeated measures model · p = < 0.0001 (Treatment difference uses placebo as the reference.) · Treatment difference: -68.6 · 95% CI -83.1 to -54.0
  • Placebo vs EvoMab 420 mg QM · sequential testing/Hochberg procedure · p = < 0.0001 (Adjusted p-value based on a combination of sequential testing and the Hochberg procedure to control the overall significance level for all primary and secondary endpoints.)Adjusted p-value is compared to 0.05 to determine statistical significance.
SecondaryPercent Change From Baseline to Week 24 in Non-HDL-C

Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 24 in Non-HDL-C
percent changePlaceboEvoMab 420 mg QM
Percent Change From Baseline to Week 24 in Non-HDL-C-6.14 ± 2.87-41.19 ± 2.01
Statistical analysis
  • Placebo vs EvoMab 420 mg QM · repeated measures model · p = < 0.0001 · Treatment difference: -35.04 · 95% CI -41.79 to -28.30Treatment difference uses placebo as the reference.
  • Placebo vs EvoMab 420 mg QM · sequential testing/Hochberg procedure · p = < 0.0001 (Adjusted p-value based on a combination of sequential testing and the Hochberg procedure to control the overall significance level for all primary and secondary endpoints.)Adjusted p-value is compared to 0.05 to determine statistical significance.
SecondaryPercent Change From Baseline to Week 24 in Apoliprotein-B (ApoB)

Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 24 in Apoliprotein-B (ApoB)
percent changePlaceboEvoMab 420 mg QM
Percent Change From Baseline to Week 24 in Apoliprotein-B (ApoB)-2.37 ± 2.70-34.85 ± 1.88
Statistical analysis
  • Placebo vs EvoMab 420 mg QM · repeated measures model · p = < 0.0001 · Treatment difference: -32.47 · 95% CI -38.82 to -26.13Treatment difference uses placebo as the reference.
  • Placebo vs EvoMab 420 mg QM · sequential testing/Hochberg procedure · p = < 0.0001 (Adjusted p-value based on a combination of sequential testing and the Hochberg procedure to control the overall significance level for all primary and secondary endpoints.)Adjusted p-value is compared to 0.05 to determine statistical significance.
SecondaryPercent Change From Baseline to Week 24 in Total Cholesterol/HDL-C Ratio

Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 24 in Total Cholesterol/HDL-C Ratio
percent changePlaceboEvoMab 420 mg QM
Percent Change From Baseline to Week 24 in Total Cholesterol/HDL-C Ratio-4.66 ± 2.60-34.96 ± 1.82
Statistical analysis
  • Placebo vs EvoMab 420 mg QM · repeated measures model · p = < 0.0001 · Treatment difference: -30.30 · 95% CI -36.40 to -24.21Treatment difference uses placebo as the reference.
  • Placebo vs EvoMab 420 mg QM · sequential testing/Hochberg procedure · p = < 0.0001 (Adjusted p-value based on a combination of sequential testing and the Hochberg procedure to control the overall significance level for all primary and secondary endpoints.)Adjusted p-value is compared to 0.05 to determine statistical significance.
SecondaryPercent Change From Baseline to Week 24 in ApoB:ApoA1 Ratio

Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 24 in ApoB:ApoA1 Ratio
percent changePlaceboEvoMab 420 mg QM
Percent Change From Baseline to Week 24 in ApoB:ApoA1 Ratio-0.63 ± 2.80-37.02 ± 1.95
Statistical analysis
  • Placebo vs EvoMab 420 mg QM · repeated measures model · p = < 0.0001 · Treatment difference: -36.38 · 95% CI -42.97 to -29.80Treatment difference uses placebo as the reference.
  • Placebo vs EvoMab 420 mg QM · sequential testing/Hochberg procedure · p = < 0.0001 (Adjusted p-value based on a combination of sequential testing and the Hochberg procedure to control the overall significance level for all primary and secondary endpoints.)Adjusted p-value is compared to 0.05 to determine statistical significance.
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation (DC), Fatal TEAEs, and Device-Related TEAEs

An adverse event (AE) is defined as any untoward medical occurrence that does not necessarily have a causal relationship with study treatment. An SAE is defined as an adverse event that: is fatal; is a life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other medically important serious event. Events were graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grading scale (1=mild; 2=moderate; 3=severe; 4=life-threatening; 5=death). Events were defined as treatment emergent if they occurred after the first dose of study drug and up to and including 30 days after the last dose or the end of study date, whichever is earlier.

Time frame:
From first dose of study drug up to and including 30 days after the last dose or end of study date (Week 24), whichever was earlier. Mean (SD) duration on study was 5.664 (0.278) and 5.608 (0.137) months for Placebo and EvoMab arms, respectively.
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation (DC), Fatal TEAEs, and Device-Related TEAEs
participantsPlaceboEvoMab 420 mg QM
All TEAEs3464
Grade ≥ 2 TEAEs2246
Grade ≥ 3 TEAEs04
Grade ≥ 4 TEAEs00
Serious TEAEs01
TEAEs Leading to DC of Study Drug01
Serious TEAEs Leading to DC of Study Drug00
Non-Serious TEAEs Leading to DC of Study Drug01
Fatal TEAEs00
Device-Related TEAEs23
Device-Related Grade ≥ 2 TEAEs00
Device-Related Grade ≥ 3 TEAEs00
Device-Related Grade ≥ 4 TEAEs00
Serious Device-Related TEAEs00
SecondaryNumber of Participants With Maximum Post-Baseline Laboratory Toxicities of Grade ≥ 3

Laboratory toxicity grading was based on NCI CTCAE grading. Grade 3 indicates severe toxicity and Grade 4 indicates life-threatening toxicity. Values representing a worsening from baseline are shown.

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants With Maximum Post-Baseline Laboratory Toxicities of Grade ≥ 3
participantsPlaceboEvoMab 420 mg QM
High Total Bilirubin - Grade 310
High Total Cholesterol - Grade 311
High Uric Acid - Grade 328
SecondaryChange From Baseline Over Time in Systolic Blood Pressure
Time frame:
Baseline, Week 4, Week 12, Week 20, Week 22, Week 24
Reported as:
Mean · mmHg
Change From Baseline Over Time in Systolic Blood Pressure
mmHgPlaceboEvoMab 420 mg QM
Change at Week 4-0.1 ± 11.3-0.7 ± 9.4
Change at Week 12-0.6 ± 10.30.3 ± 9.6
Change at Week 20-2.1 ± 7.70.1 ± 10.1
Change at Week 221.0 ± 10.91.1 ± 10.0
Change at Week 24-0.6 ± 11.40.6 ± 10.7
SecondaryChange From Baseline Over Time in Diastolic Blood Pressure
Time frame:
Baseline, Week 4, Week 12, Week 20, Week 22, Week 24
Reported as:
Mean · mmHg
Change From Baseline Over Time in Diastolic Blood Pressure
mmHgPlaceboEvoMab 420 mg QM
Change at Week 4-2.5 ± 9.5-1.5 ± 7.3
Change at Week 12-2.2 ± 10.00.5 ± 8.9
Change at Week 20-3.3 ± 7.6-0.6 ± 7.7
Change at Week 22-1.5 ± 9.32.9 ± 8.0
Change at Week 24-0.5 ± 9.00.3 ± 8.6
SecondaryChange From Baseline Over Time in Heart Rate
Time frame:
Baseline, Week 4, Week 12, Week 20, Week 22, Week 24
Reported as:
Mean · beats per minute
Change From Baseline Over Time in Heart Rate
beats per minutePlaceboEvoMab 420 mg QM
Change at Week 42.1 ± 11.00.1 ± 10.8
Change at Week 12-0.5 ± 11.5-1.3 ± 10.2
Change at Week 20-1.1 ± 10.31.1 ± 11.5
Change at Week 221.3 ± 13.5-0.6 ± 11.3
Change at Week 240.2 ± 13.0-1.8 ± 11.8
SecondaryNumber of Participants Testing Positive for Anti-Evolocumab Antibodies
Time frame:
up to Week 24
Reported as:
Count of participants · Participants
Number of Participants Testing Positive for Anti-Evolocumab Antibodies
ParticipantsPlaceboEvoMab 420 mg QM
Binding antibody positive at anytime—0
Neutralizing antibody positive at anytime—0
SecondarySerum Evolocumab Concentrations Over Time
Time frame:
Week 12, Week 22, Week 24
Reported as:
Mean · ng/mL
Serum Evolocumab Concentrations Over Time
ng/mLEvoMab 420 mg QM
Week 1222400 ± 14700
Week 2264900 ± 34400
Week 2425800 ± 19200

Adverse events

Collected over Fatal AEs: from first dose date to end of study date (Week 24); non-fatal AEs: from first dose of study drug up to 30 days after last dose or end of study date, whichever was earlier. Mean (SD) duration on study was 5.664 (0.278) and 5.608 (0.137) months for the Placebo and EvoMab arms, respectively.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo SC QM0/53 (0%)0/53 (0%)19/53 (35.8%)
EvoMab 420 mg SC QM0/105 (0%)1/104 (1%)41/104 (39.4%)
Most frequent serious events
Most frequent serious events
EventPlacebo SC QMEvoMab 420 mg SC QM
CholelithiasisHepatobiliary disorders0/531/104
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlacebo SC QMEvoMab 420 mg SC QM
NasopharyngitisInfections and infestations6/5312/104
HeadacheNervous system disorders1/5311/104
GastroenteritisInfections and infestations4/535/104
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/537/104
InfluenzaInfections and infestations2/536/104
Upper respiratory tract infectionInfections and infestations1/536/104
PyrexiaGeneral disorders3/533/104
CoughRespiratory, thoracic and mediastinal disorders3/532/104
RhinitisInfections and infestations2/530/104
Blood creatine phosphokinase increasedInvestigations2/531/104

Baseline characteristics

Full Analysis Set: participants who were randomized and dosed.

Age, Continuous
Age, Continuous(years)PlaceboEvoMab 420 mg QMTotal
Mean13.7 ± 2.513.7 ± 2.313.7 ± 2.4
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEvoMab 420 mg QMTotal
Female276188
Male264369
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboEvoMab 420 mg QMTotal
Hispanic or Latino7613
Not Hispanic or Latino4698144
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboEvoMab 420 mg QMTotal
Asian022
Black (or African American)022
White4489133
Other, Not Specified91120
Stratification Factor: Age Group
Stratification Factor: Age Group(participants)PlaceboEvoMab 420 mg QMTotal
< 14 years254873
≥ 14 years285684
Stratification Factor: Screening LDL-C Level
Stratification Factor: Screening LDL-C Level(participants)PlaceboEvoMab 420 mg QMTotal
< 160 mg/dL163349
≥ 160 mg/dL3771108
LDL-C
LDL-C(mg/dL)PlaceboEvoMab 420 mg QMTotal
Mean183.0 ± 47.2185.0 ± 45.0184.3 ± 45.6
Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)
Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)(mg/dL)PlaceboEvoMab 420 mg QMTotal
Mean200.2 ± 48.2203.8 ± 47.3202.6 ± 47.5

6 further baseline measures are reported on the registry.

08

Study locations

66 sites
  • Research Site
    Farmington, Connecticut 06032, United States
  • Research Site
    Wilmington, Delaware 19803, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Towson, Maryland 21204, United States
  • Research Site
    Minneapolis, Minnesota 55454, United States
  • Research Site
    Bronx, New York 10467, United States
  • Research Site
    Asheville, North Carolina 28803, United States
  • Research Site
    Cincinnati, Ohio 45227, United States
  • Research Site
    Pittsburgh, Pennsylvania 15224, United States
  • Research Site
    Nashville, Tennessee 37212, United States
  • Research Site
    Salt Lake City, Utah 84113, United States
  • Research Site
    Morgantown, West Virginia 26506, United States
  • Research Site
    Camperdown, New South Wales 2050, Australia
  • Research Site
    Feldkirch, 6800, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Wien, 1090, Austria
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    La Louvière, 7100, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Fortaleza, Ceará 60430-270, Brazil
  • Research Site
    Brasília, Distrito Federal 71625-175, Brazil
  • Research Site
    Vitória, Espírito Santo 29055-450, Brazil
  • Research Site
    São Paulo, 04040-000, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    Chicoutimi, Quebec G7H 5H6, Canada
  • Research Site
    Chicoutimi, Quebec G7H 7K9, Canada
  • Research Site
    Quebec, G1V 4W2, Canada
  • Research Site
    Barranquilla, Atlántico 080020, Colombia
  • Research Site
    Floridablanca, Santander, Colombia
  • Research Site
    Ostrava-Poruba, 708 52, Czechia
  • Research Site
    Praha 5, 150 06, Czechia
  • Research Site
    Svitavy, 568 25, Czechia
  • Research Site
    Helsinki, 00029, Finland
  • Research Site
    Kuopio, 70029, Finland
  • Research Site
    Athens, 17674, Greece
  • Research Site
    Thessaloniki, 54642, Greece
  • Research Site
    Budapest, 1094, Hungary
  • Research Site
    Palermo, 90127, Italy
  • Research Site
    Pisa, 56124, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Roma, 00165, Italy
  • Research Site
    Torino, 10126, Italy
  • Research Site
    Kota Bharu, Kelantan 16150, Malaysia
  • Research Site
    Amsterdam, 1105 AZ, Netherlands
  • Research Site
    Christchurch, 8011, New Zealand
  • Research Site
    Bergen, 5021, Norway
  • Research Site
    Oslo, 0586, Norway
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Guimaraes, 4835-044, Portugal
  • Research Site
    Moscow, 125412, Russian Federation
  • Research Site
    Saint Petersburg, 191025, Russian Federation
  • Research Site
    Ljubljana, 1000, Slovenia
  • Research Site
    Pretoria, Gauteng 0087, South Africa
  • Research Site
    Parow, Western Cape 7505, South Africa
  • Research Site
    Cordoba, Andalucía 14004, Spain
  • Research Site
    Sevilla, Andalucía 41013, Spain
  • Research Site
    Barcelona, Cataluña 08036, Spain
  • Research Site
    A Coruña, Galicia 15001, Spain
  • Research Site
    Lugo, Galicia 27003, Spain
  • Research Site
    Geneva 14, 1211, Switzerland
  • Research Site
    Reinach, 4153, Switzerland
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Ankara, 06500, Turkey
  • Research Site
    Izmir, 35100, Turkey
  • Research Site
    Birmingham, B4 6NH, United Kingdom
  • Research Site
    London, WC1N 3JH, United Kingdom
09

References and documents

Publications

  • Santos RD, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE, Hamer A, Bridges I, Bartuli A, Bergeron J, Szamosi T, Santra S, Stefanutti C, Descamps OS, Greber-Platzer S, Luirink I, Kastelein JJP, Gaudet D; HAUSER-RCT Investigators. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 Oct 1;383(14):1317-1327. doi: 10.1056/NEJMoa2019910. Epub 2020 Aug 29. PubMed 32865373 ↗
  • Gaudet D, Langslet G, Gidding SS, Luirink IK, Ruzza A, Kurtz C, Lu C, Somaratne R, Raal FJ, Wiegman A. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. J Clin Lipidol. 2018 Sep-Oct;12(5):1199-1207. doi: 10.1016/j.jacl.2018.05.007. Epub 2018 May 22. PubMed 30318065 ↗
  • Gaudet D, Ruzza A, Bridges I, Maruff P, Schembri A, Hamer A, Mach F, Bergeron J, Gaudet I, Pierre JS, Kastelein JJP, Hovingh GK, Wiegman A, Raal FJ, Santos RD. Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia. J Clin Lipidol. 2022 Sep-Oct;16(5):676-684. doi: 10.1016/j.jacl.2022.07.005. Epub 2022 Jul 21. PubMed 36210291 ↗
  • Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Oct 20;10(10):CD011748. doi: 10.1002/14651858.CD011748.pub3. PubMed 33078867 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Nov 2019, 44 months.

Results were first posted in Jul 2020, 7 months after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 44 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2015
First posted
Mar 19, 2015
StartActual
Mar 24, 2016
Primary completionActual
Nov 25, 2019
CompletionActual
Nov 25, 2019
Results first posted
Jul 15, 2020
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02392559
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 19, 2015
Start date
Mar 24, 2016
Primary completion
Nov 25, 2019
Completion
Nov 25, 2019
Results posted
Jul 15, 2020
Last update
Nov 8, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion